Antimicrobial surveillance in South Australian prisons: a pilot study
Ajmal Dalwai A * and Nadine Hillock A BA
B
Abstract
This study aimed to determine the feasibility of capturing antimicrobial usage data from prisons for inclusion in the Antimicrobial Use and Resistance in Australia (AURA) surveillance system and to analyse 2021 and 2022 South Australian (SA) usage data for notable trends.
Monthly antimicrobial supply data for eight SA prisons were collected. Antimicrobial volume was converted into the World Health Organization metric, defined daily doses (DDD). Usage rates were calculated relative to prison occupied bed days (OBD).
Annual usage of systemic antimicrobials across eight SA prisons totalled 26,448 DDD and 23,526 DDD in 2021 and 2022 respectively. Antibacterials accounted for 80.6% of all antimicrobials dispensed during the study period. The average antibacterial usage rate in female prisons was higher on average than in male prisons. The state-wide systemic antibacterial usage rate in SA prisons declined by 11.3% from 23.8 DDDs/1000 OBD in 2021 to 21.1 DDDs/1000 OBD. Doxycycline, amoxicillin, flucloxacillin, amoxicillin-clavulanic acid, and cefalexin accounted for 72% of the total systemic antibacterial usage rate. Variation in the oral and topical antifungal agents used and the rate of use was observed between prisons.
This SA pilot study demonstrates the feasibility of including prisons in routine national antimicrobial surveillance using similar methodology to hospital surveillance. The contributing facilities comprised 6.1% of all Australian prison beds, and extrapolation of the results suggests that the identified gap in surveillance may equate to over 400,000 DDD per annum in prisons nationwide, equating to approximately 5% of hospital inpatient antimicrobial usage.
Keywords: antibacterial, antibiotic, antimicrobial stewardship, antimicrobial surveillance, antimicrobials, prisons.
References
1 Antimicrobial Resistance Collaborators.. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 2022; 399(10325): 629-55.
| Crossref | Google Scholar | PubMed |
2 Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: a global multifaceted phenomenon. Pathog Glob Health 2015; 109(7): 309-18.
| Crossref | Google Scholar | PubMed |
3 World Health Organization. Global action plan on antimicrobial resistance. 2015. Available at https://iris.who.int/bitstream/handle/10665/193736/9789241509763_eng.pdf
4 Australian Government. Australia’s National Antimicrobial Resistance Strategy – 2020 and beyond. 2022. Available at https://www.amr.gov.au/resources/australias-national-antimicrobial-resistance-strategy-2020-and-beyond
5 Bick JA. Infection control in jails and prisons. Clin Infect Dis 2007; 45(8): 1047-55.
| Crossref | Google Scholar | PubMed |
6 Maruschak LM, Berzofsky M, Unangst J. Medical Problems of State and Federal Prisoners and Jail Inmates, 2011–12. Office of Justice Programs, Bureau of Justice Statistics; 2015. Available at https://bjs.ojp.gov/content/pub/pdf/mpsfpji1112.pdf
7 Mukherjee DV, Herzig CT, Jeon CY, et al. Prevalence and risk factors for Staphylococcus aureus colonization in individuals entering maximum-security prisons. Epidemiol Infect 2014; 142(3): 484-93.
| Crossref | Google Scholar | PubMed |
8 Australian Institute of Health and Welfare. Adult in prisons. 2023 Available at https://www.aihw.gov.au/reports/australias-welfare/adult-prisoners
9 Hampton S, Blomgren D, Roberts J, et al. Prescribing for people in custody. Aust Prescr 2015; 38(5): 160-3.
| Crossref | Google Scholar | PubMed |
10 Australian Bureau of Statistics. Corrective Service, Australia. 2024. Available at https://www.abs.gov.au/statistics/people/crime-and-justice/corrective-services-australia/latest-release#data-download
11 DCS. How we do it: Prison stats. Department of Correctional Services (DCS); 2022. Available at https://www.corrections.sa.gov.au/about/what-we-do/how-we-do-it
12 Australian Institute of Health and Wellbeing. Medication use by Australia’s prisoners 2015: how is it different from the general community? 2016. Available at https://www.aihw.gov.au/reports/prisoners/medication-use-by-australias-prisoners-2015/contents/table-of-contents
13 Di Giuseppe G, Lanzano R, Silvestro A, et al. Pattern and Appropriateness of Antimicrobial Prescriptions for Upper Respiratory Tract and Dental Infections in Male Prisoners in Italy. Antibiotics 2021; 10(11): 1419.
| Crossref | Google Scholar | PubMed |
14 Szewczyk BR, Tenner R, Grussing E, et al. Establishing a baseline of antibiotic use in Massachusetts jails reveals heterogeneity in quantity of prescriptions and duration of therapy. Antimicrob Steward Healthc Epidemiol 2023; 3(1): e106.
| Crossref | Google Scholar | PubMed |
15 Australian Government. Medicare: What’s covered. 2023. Available at https://www.health.gov.au/topics/medicare/about/what-medicare-covers
16 SA Health. National Antimicrobial Utilisation Surveillance Program. 2024. Available at https://www.sahealth.sa.gov.au/nausp
17 Australian Commission on Safety and Quality in Health Care. About the AURA surveillance system. 2024. Available at https://www.safetyandquality.gov.au/our-work/antimicrobial-resistance/antimicrobial-use-and-resistance-australia-surveillance-system/about-aura-surveillance-system
18 Australian Commission on Safety and Quality in Health Care. AURA 2021: Fourth Australian report on antimicrobial use and resistance in human health. 2021. Available at https://www.safetyandquality.gov.au/publications-and-resources/resource-library/aura-2021-fourth-australian-report-antimicrobial-use-and-resistance-human-health
19 Australian Government Department of Health and Aged Care, SA Health. Antimicrobial Use in Australian Hospitals. National Antimicrobial Utilisation Surveillance Program Annual Report, 2021. 2023. Available at https://www.amr.gov.au/sites/default/files/2024-01/antimicrobial-use-in-australian-hospitals-national-antimicrobial-utilisation-surveillance-program-annual-report-2021.pdf
20 World Health Organization (WHO). Defined Daily Dose (DDD): Definition and general considerations. 2018. Available at https://www.whocc.no/ddd/definition_and_general_considera/
21 National Health and Medical Research Council. Ethical Considerations in Quality Assurance and Evaluation Activities. 2014. Available at https://www.nhmrc.gov.au/about-us/resources/ethical-considerations-quality-assurance-and-evaluation-activities
22 Fukushige M, Ngo NH, Lukmanto D, et al. Effect of the COVID-19 pandemic on antibiotic consumption: A systematic review comparing 2019 and 2020 data. Front Public Health 2022; 10: 946077.
| Crossref | Google Scholar | PubMed |
23 Nandi A, Pecetta S, Bloom DE. Global antibiotic use during the COVID-19 pandemic: analysis of pharmaceutical sales data from 71 countries, 2020-2022. EClinicalMedicine 2023; 57: 101848.
| Crossref | Google Scholar | PubMed |
24 Zanichelli V, Monnier AA, Gyssens IC, et al. Variation in antibiotic use among and within different settings: a systematic review. J Antimicrob Chemother 2018; 73(suppl_6): vi17-29.
| Crossref | Google Scholar | PubMed |
25 National Antimicrobial Prescribing Survey (NAPS). Melbourne Health. 2024. Available at https://www.naps.org.au/Default.aspx
26 Australian Commission on Safety and Quality in Health Care. Antimicrobial use and appropriateness in the community: 2020-2021. 2022. Available at https://www.safetyandquality.gov.au/publications-and-resources/resource-library/antimicrobial-use-and-appropriateness-community-2020-2021
27 Mazzoleni L, Zovi A, D’Angelo C, et al. Planning and development of an antimicrobial stewardship program in penitentiary facilities: strategies to optimize therapeutic prescribing and reduce the incidence of antibiotic resistance. Front Public Health 2023; 11: 1233522.
| Crossref | Google Scholar | PubMed |